Clinical Trials

SARC-005: A phase II trial of ABSK043, an oral PD1 inhibitor, in patients with selected sarcomas

Link :
Status : PENDING
Population : Angiogenic sarcomas (EHE, intimal sarcomas, H&N angiosarcomas)
Description : ABSK043: 800mg PO BID
PI : A. Razak
Centers Opened : PMH
Phase : II
IIST/Pharma : IIST